NASDAQ · Healthcare

CRISPR Therapeutics AG

CRSP · Biotechnology

$53.56

▲ 1.93 (3.74%)

Data cached · refreshes every 10 min

Insufficient data to generate a complete Graham analysis.

Overall Grade

Defensive

Enterprising

Profitability N/A

Fin. Health C

Years to Pay Off Debt -0.4 yrs

Working Capital vs Long-Term Debt $1.6B

Working Capital $1.8B

Valuation D

Price-to-Book 2.69x

Cash Flow F

Free Cash Flow -$371M

Owner Earnings -$536M

1/6

Graham Score

Speculative

Defensive — Graham's strict criteria (P/B, P/E, dividends, stability) · Enterprising — Profitability & cash flow focused, accepts higher valuations for quality

Metric Explanations

What each dimension measures and where the thresholds come from.

Market Data

Market Cap $5.2B

Enterprise Value $3.2B

P/E (TTM) -13.34

Dividend Yield N/A

Exchange NASDAQ

Key Margins

Gross Profit N/A

Operating Margin N/A

Net Margin N/A

Company Info

Sector Healthcare

Industry Biotechnology

Country Switzerland

Visit website

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Showing Key Metrics

Income Highlights

Metric	2025	2024	2023	2022
Gross Profit %	N/A •	-244.8%	64.8%	-25,186.7%
Operating Margin %	N/A •	-1,333.0%	-60.1%	-154,394.7%
Net Income %	N/A •	-1,046.4%	-41.5%	-149,122.7%
Diluted EPS	-6.47 ▼	-4.34	-1.94	-8.36

Balance Sheet Highlights

Metric	2025	2024	2023	2022	2021
Total Assets	$2.3B	$2.2B	$2.2B	$2.2B	N/A
Total Debt	$207M ↓	$224M	$239M	$244M	N/A
Working Capital	$1.8B ▼	$1.8B	$1.8B	$1.7B	N/A
Years to Pay Debt	-0.36	-0.61	-1.55	-0.38	N/A

Cash Flow Highlights

Metric	2025	2024	2023	2022	2021
Free Cash Flow	-$371M ▼	-$145M	-$272M	-$533M	N/A
Owner Earnings	-$536M	-$345M	-$122M	-$589M	N/A
CapEx % of Net Income	N/A	N/A	N/A	N/A	N/A

Income Statement

	2025	2024	2023	2022
Tax Rate For Calcs	0	0	0	0
Normalized EBITDA	-645,092	-447,307	-202,701	-648,989
Net Income From Continuing Operation Net Minority Interest	-581,599	-366,252	-153,610	-650,175
Reconciled Depreciation	19,479	19,259	19,837	24,172
Reconciled Cost Of Revenue	213,480	120,667	130,250	110,250
EBITDA	-645,092	-447,307	-202,701	-648,989
EBIT	-664,571	-466,566	-222,538	-673,161
Normalized Income	-581,599	-366,252	-153,610	-650,175
Net Income From Continuing And Discontinued Operation	-581,599	-366,252	-153,610	-650,175
Total Expenses	664,571	501,566	592,538	673,597
Total Operating Income As Reported	-664,571	-466,566	-222,538	-673,161
Diluted Average Shares	89,925	84,359	79,221	77,747
Basic Average Shares	89,925	84,359	79,221	77,747
Diluted EPS	0	0	0	0
Basic EPS	0	0	0	0
Diluted NI Availto Com Stockholders	-581,599	-366,252	-153,610	-650,175
Net Income Common Stockholders	-581,599	-366,252	-153,610	-650,175
Net Income	-581,599	-366,252	-153,610	-650,175
Net Income Including Noncontrolling Interests	-581,599	-366,252	-153,610	-650,175
Net Income Continuous Operations	-581,599	-366,252	-153,610	-650,175
Tax Provision	3,634	3,587	2,888	-325
Pretax Income	-577,965	-362,665	-150,722	-650,500
Other Income Expense	86,606	103,901	71,816	22,661
Other Non Operating Income Expenses	86,606	103,901	71,816	22,661
Operating Income	-664,571	-466,566	-222,538	-673,161
Operating Expense	451,091	380,899	462,288	563,347
Other Operating Expenses	-3,510	-2,314	-1,206	-762
Research And Development	381,059	310,236	387,332	461,645
Selling General And Administration	73,542	72,977	76,162	102,464
General And Administrative Expense	73,542	72,977	76,162	102,464
Other Gand A	73,542	72,977	76,162	102,464
Gross Profit	-213,480	-85,667	239,750	-109,814
Cost Of Revenue	213,480	120,667	130,250	110,250
Total Revenue	0	35,000	370,000	436
Operating Revenue	0	35,000	370,000	436

Balance Sheet

	2025	2024	2023	2022	2021
Treasury Shares Number	115	170	170	180
Ordinary Shares Number	95,894	85,742	80,044	78,512
Share Issued	96,010	85,912	80,215	78,693
Total Debt	206,746	223,693	238,632	244,021
Tangible Book Value	1,921,813	1,932,080	1,882,787	1,875,408
Invested Capital	1,921,813	1,932,080	1,882,803	1,875,479
Working Capital	1,836,551	1,849,350	1,799,287	1,731,919
Net Tangible Assets	1,921,813	1,932,080	1,882,787	1,875,408
Capital Lease Obligations	206,746	223,693	238,632	244,021
Common Stock Equity	1,921,813	1,932,080	1,882,803	1,875,479
Total Capitalization	1,921,813	1,932,080	1,882,803	1,875,479
Total Equity Gross Minority Interest	1,921,813	1,932,080	1,882,803	1,875,479
Stockholders Equity	1,921,813	1,932,080	1,882,803	1,875,479
Gains Losses Not Affecting Retained Earnings	4,821	1,840	1,913	-15,647
Other Equity Adjustments	4,821	1,840	1,913	-15,647
Treasury Stock	60	62	62	63
Retained Earnings	-1,947,551	-1,365,952	-999,700	-846,090
Additional Paid In Capital	3,861,516	3,293,556	2,878,155	2,734,838
Capital Stock	3,087	2,698	2,497	2,441
Common Stock	3,087	2,698	2,497	2,441
Total Liabilities Net Minority Interest	343,430	309,954	346,768	367,578
Total Non Current Liabilities Net Minority Interest	194,310	222,172	237,977	246,471
Other Non Current Liabilities	6,142	3,444	958	5,969
Non Current Deferred Liabilities	0	12,323	14,012	12,323
Non Current Deferred Revenue	0	12,323	14,012	12,323
Long Term Debt And Capital Lease Obligation	188,168	206,405	223,007	228,179
Long Term Capital Lease Obligation	188,168	206,405	223,007	228,179
Current Liabilities	149,120	87,782	108,791	121,107
Other Current Liabilities	13,113	10,417	5,141	20
Current Deferred Liabilities	15,771	3,845	4,105	0
Current Deferred Revenue	15,771	3,845	4,105	0
Current Debt And Capital Lease Obligation	18,578	17,288	15,625	15,842
Current Capital Lease Obligation	18,578	17,288	15,625	15,842
Payables And Accrued Expenses	101,658	56,232	83,920	105,245
Current Accrued Expenses	89,407	41,072	45,335	77,682
Payables	12,251	15,160	38,585	27,563
Total Tax Payable	1,113	451	438	135
Accounts Payable	11,138	14,709	38,147	27,428
Total Assets	2,265,243	2,242,034	2,229,571	2,243,057
Total Non Current Assets	279,572	304,902	321,493	390,031
Other Non Current Assets	31,997	27,348	13,566	16,275
Investments And Advances		0	1,973	53,130	0
Investmentin Financial Assets		0	1,973	53,130	0
Available For Sale Securities			1,973	53,130
Goodwill And Other Intangible Assets		0	16	71	125
Net PPE	247,575	277,554	305,938	320,555
Accumulated Depreciation	-91,052	-72,272	-53,433	-33,832
Gross PPE	338,627	349,826	359,371	354,387
Leases	146,667	145,852	143,260	141,680
Construction In Progress	3,955	6,118	8,859	6,162
Other Properties	175,299	185,469	195,404	194,818
Machinery Furniture Equipment	12,706	12,387	11,848	11,727
Current Assets	1,985,671	1,937,132	1,908,078	1,853,026
Other Current Assets	9,843	8,306	14,386	37,708
Prepaid Assets					38,079
Receivables	0	25,000	200,000	0
Accounts Receivable	0	25,000	200,000	0
Cash Cash Equivalents And Short Term Investments	1,975,828	1,903,826	1,693,692	1,815,318
Other Short Term Investments	1,628,269	1,605,569	1,304,215	1,603,433
Cash And Cash Equivalents	347,559	298,257	389,477	211,885

Cash Flow

	2025	2024	2023	2022	2021
Free Cash Flow	-370,928	-144,675	-272,345	-532,929
Issuance Of Capital Stock	398,090	300,695	32,721	970
Capital Expenditure	-25,914	-1,901	-11,970	-37,188
End Cash Position	359,078	309,776	401,068	224,060
Beginning Cash Position	309,776	401,068	224,060	939,944
Effect Of Exchange Rate Changes	95	-21	73	-80
Changes In Cash	49,207	-91,271	176,935	-715,804
Financing Cash Flow	426,026	331,984	62,664	38,592
Cash Flow From Continuing Financing Activities	426,026	331,984	62,664	38,592
Proceeds From Stock Option Exercised	27,936	31,289	29,943	37,622
Net Common Stock Issuance	398,090	300,695	32,721	970
Common Stock Issuance	398,090	300,695	32,721	970
Investing Cash Flow	-31,805	-280,481	374,647	-258,655
Cash Flow From Continuing Investing Activities	-31,805	-280,481	374,647	-258,655
Net Investment Purchase And Sale	-5,891	-278,580	386,617	-221,467
Sale Of Investment	1,011,979	1,207,799	1,452,528	1,196,333
Purchase Of Investment	-1,017,870	-1,486,379	-1,065,911	-1,417,800
Net Intangibles Purchase And Sale	-25,000	0	-2,500	0
Purchase Of Intangibles	-25,000	0	-2,500	0
Net PPE Purchase And Sale	-914	-1,901	-9,470	-37,188
Purchase Of PPE	-914	-1,901	-9,470	-37,188
Operating Cash Flow	-345,014	-142,774	-260,375	-495,741
Cash Flow From Continuing Operating Activities	-345,014	-142,774	-260,375	-495,741
Change In Working Capital	71,882	156,270	-193,585	19,845
Change In Other Working Capital	-5,607	-6,356	3,333	14,299
Change In Other Current Liabilities	4,258	9,624	110	-1,521
Change In Payables And Accrued Expense	44,894	-27,283	-20,247	5,164
Change In Prepaid Assets	3,337	5,285	23,219	1,598
Change In Receivables	25,000	175,000	-200,000	305
Changes In Account Receivables	25,000	175,000	-200,000	305
Other Non Cash Items	72,725	-38,618	-14,045	12,470
Stock Based Compensation	72,499	86,567	81,028	97,947
Amortization Of Securities					14,109
Depreciation Amortization Depletion	19,479	19,259	19,837	24,172
Depreciation And Amortization	19,479	19,259	19,837	24,172
Depreciation	19,400	19,200
Net Income From Continuing Operations	-581,599	-366,252	-153,610	-650,175

These metrics estimate what CRISPR Therapeutics AG is worth based on its fundamentals — independent of what the market currently prices it at. Graham's Fair Value and NCAV are conservative floors rooted in 1930s–60s principles. EPV assumes zero growth. None are price targets — they are reference points for judging whether the current price offers a margin of safety.

Graham's Fair Value

N/A (negative EPS)

Margin of Safety

—

Market Cap ÷ Company Value

1.00

P/B Ratio

2.69

Warren's Owner Earnings

-$536M

Latest fiscal year

Graham's 7 Criteria

Defensive Investor Checklist

1/6 — Speculative Investor

❌ Adequate Size

$0M

vs > $1.5B revenue

✅ Strong Financial Condition

13.32x

vs Current Ratio > 2.0x

❌ Earnings Stability

4 loss years (4 yrs data)

vs No negative EPS years

❌ Dividend Record

No dividend

vs Uninterrupted dividends

❌ Moderate P/E Ratio

-13.3x

vs P/E ≤ 15.0x

❌ Moderate Price-to-Book

2.69x P/B (P/E×P/B: -35.9)

vs P/B ≤ 1.5x | P/E × P/B ≤ 22.5

Net Current Asset Value

$17.03

Trading at 3.1x NCAV. Expected for most quality businesses — NCAV was designed to find depression-era bargains and rarely applies to modern profitable companies.

"Buy at two-thirds of net current assets." — Graham

Earnings Power Value

$-76.57

Per share, no-growth floor. Compare to current price.

Cash Flow Analysis

Metric	2025	2024	2023	2022	2021
Capital Expenditure % of Net Income	N/A	N/A	N/A	N/A	N/A
Repurchase of Capital Stock	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$371M ▼	-$145M ▲	-$272M ▲	-$533M •	N/A •
Warren's Owner Earnings	-$536M	-$345M	-$122M	-$589M	N/A

Peers & Industry Comparison

Biotechnology — Auto-detected peers

Company	Price	Market Cap	P/E	Gross Margin	Net Margin	Revenue
CRSP	$53.56	$5.2B	-13.34	N/A	N/A	$0M
AMGN Amgen Inc.	$322.38	$174.0B	22.4	71.4%	21.0%	$37.2B
GILD Gilead Sciences, Inc.	$132.44	$164.4B	19.5	78.8%	28.9%	$29.4B
BIIB Biogen Inc.	$187.14	$27.6B	20.1	78.7%	13.8%	$9.9B
REGN Regeneron Pharmaceuticals, Inc.	$708.41	$74.3B	17.3	43.9%	29.6%	$14.9B
VRTX Vertex Pharmaceuticals Incorpor	$428.97	$109.1B	28.0	53.7%	32.9%	$12.0B

"The management of a business is its most important single factor — more important than market position, patents, or financial structure."

— Benjamin Graham

Capital Allocation & Alignment

Insider Ownership

5.90%

Moderate — some alignment with shareholders

Return on Equity (ROE)

-30.3%

Weak — poor returns on equity

Return on Assets (ROA)

-25.7%

Poor — assets are not generating adequate returns

Debt Trend YoY

-7.6% YoY

Debt is declining — management is deleveraging

Leadership Team

Samarth Kulkarni Ph.

CEO & Chairman

Age 47

Pay: $1,434,715

Raju Yashaswi Prasad Ph.

Chief Financial Officer

Age 41

Pay: $779,557

Shaun Foy CFA

Co-Founder

Emmanuelle Marie Charpentier Ph.

Co-Founder & Scientific Advisory Board Member

Craig Mello Ph.

Scientific Founder & Advisory Board Member

Top Institutional Holders

Institution	% Owned	Shares
ARK Investment Management, LLC	10.91%	10,522,057
Blackrock Inc.	7.79%	7,508,178
Orbis Allan Gray Ltd	6.17%	5,950,145
Capital International Investors	6.11%	5,892,745
State Street Corporation	3.89%	3,753,440
T. Rowe Price Investment Management, Inc.	3.35%	3,226,595
GSK plc	3.34%	3,220,627
UBS Group AG	2.62%	2,524,144

⚠️ Short interest exceeds 20% — heavy bearish bets

Risk Analysis

Beta (Market Risk)

1.74

High volatility — moves more than the market

Short Interest

27.0% of float

Heavy short selling — market has significant bearish bets

Debt-to-Equity

0.11x

Conservative balance sheet — low financial risk

Current Ratio